Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Glycemic effect of pancreatic preproglucagon in mouse sleeve gastrectomy
Ki-Suk Kim, Chelsea R. Hutch, Landon Wood, Irwin J. Magrisso, Randy J. Seeley, Darleen A. Sandoval
Ki-Suk Kim, Chelsea R. Hutch, Landon Wood, Irwin J. Magrisso, Randy J. Seeley, Darleen A. Sandoval
View: Text | PDF
Research Article Endocrinology Metabolism

Glycemic effect of pancreatic preproglucagon in mouse sleeve gastrectomy

  • Text
  • PDF
Abstract

Intestinally derived glucagon-like peptide-1 (GLP-1), encoded by the preproglucagon (Gcg) gene, is believed to function as an incretin. However, our previous work questioned this dogma and demonstrated that pancreatic peptides rather than intestinal Gcg peptides, including GLP-1, are a primary regulator of glucose homeostasis in normal mice. The objective of these experiments was to determine whether changes in nutrition or alteration of gut hormone secretion by bariatric surgery would result in a larger role for intestinal GLP-1 in the regulation of insulin secretion and glucose homeostasis. Multiple transgenic models, including mouse models with intestine- or pancreas tissue–specific Gcg expression and a whole-body Gcg-null mouse model, were generated to study the role of organ-specific GLP-1 production on glucose homeostasis under dietary-induced obesity and after weight loss from bariatric surgery (vertical sleeve gastrectomy; VSG). Our findings indicated that the intestine is a major source of circulating GLP-1 after various nutrient and surgical stimuli. However, even with the 4-fold increase in intestinally derived GLP-1 with VSG, it is pancreatic peptides, not intestinal Gcg peptides, that are necessary for surgery-induced improvements in glucose homeostasis.

Authors

Ki-Suk Kim, Chelsea R. Hutch, Landon Wood, Irwin J. Magrisso, Randy J. Seeley, Darleen A. Sandoval

×

Figure 3

GLP-1 secretion and GLP-1R signaling is conserved during HFD ingestion.

Options: View larger image (or click on image) Download as PowerPoint
GLP-1 secretion and GLP-1R signaling is conserved during HFD ingestion.
...
(A) A schematic representation of the experimental timeline for the chow versus high-fat diet (HFD) studies. (B and C) Pancreatic (B) and intestinal (C) total GLP-1 response to a liquid mixed-meal was similar between chow and HFD and was undetectable in GcgRAΔNull mice (2-way ANOVA). (D) Five-hour fasting blood glucose levels were significantly greater in HFD- versus chow-fed mice across all mouse genotypes (2-way ANOVA; main effect of diet). (E–H) Glucose response to an oral glucose load preceded by an i.p. injection of saline (Sal) or exendin 9-39 (Ex9) in chow- or HFD-fed control in (E) control animals (PDX1Cre and VilCre; 3-way ANOVA; time x drug x diet), in (F) GcgRAΔPdx1Cre (3-way ANOVA; time × drug), in (G) GcgRAΔNull (3-way ANOVA; time × diet), and in (H) GcgRAΔVilCre mice (3-way ANOVA; time × diet). For panels (E–H) *P < 0.05; **P < 0.01; P < 0.001 for chow versus HFD in both drug-treated groups; #P < 0.05; ##P < 0.01 for Sal versus Ex9 in both diet groups. Glucose incremental area under the curve (iAUC) during the oral glucose tolerance test (OGTT) in chow- (I) or HFD (J)-fed GcgRA mouse cohorts. *P < 0.05; **P < 0.01; ***P < 0.001 (2-way ANOVA; drug × genotype). All data were obtained from cohorts 2 and 3, each animal was tested once per condition, and data are represented as Mean ± SEM. OGTT data from Pdx1Cre and VilCre were combined for the Ctrl group (D, E, I, and J). Ctrl: Chow (n = 7 from Pdx1Cre, n = 7 from VilCre), HFD (n = 6 from Pdx1Cre, n = 7 from VilCre); GcgRAΔPdx1Cre: Chow (n = 8), HFD (n = 11); GcgRAΔNull: Chow (n = 13), HFD (n = 11); GcgRAΔVilCre: Chow (n = 7), HFD (n = 7).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts